Search

Displaying results 9121 - 9130 of 9682 in total
  1. Drug

    Adrulipase alfa

    go.drugbank.com/drugs/DB15004
    Investigational

    MS-1819 is under investigation in clinical trial NCT03481803 (A Phase IIa Study With Escalating Dose of MS1819-SD).

  2. Drug

    Edasalonexent

    go.drugbank.com/drugs/DB15010
    Investigational

    Edasalonexent is under investigation in clinical trial NCT01511900 (A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes).

  3. Drug

    Mongersen

    go.drugbank.com/drugs/DB15019
    Investigational

    Mongersen is under investigation in clinical trial NCT02957474 (A Study to Evaluate the Effect of Food, Formulation Strength, and a Proton Pump Inhibitor on GED 0301 Pharmacokinetics in Healthy Adult Subjects

  4. Drug

    BMS-791826

    go.drugbank.com/drugs/DB15023
    Investigational

    BMS-791826 is under investigation in clinical trial NCT03198013 (A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males).

  5. Drug

    CXA-10

    go.drugbank.com/drugs/DB15026
    Investigational

    CXA-10 is under investigation in clinical trial NCT03422510 (FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)).

  6. Drug

    TP-271

    go.drugbank.com/drugs/DB15040
    Investigational

    TP-271 is under investigation in clinical trial NCT02724085 (A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271).

  7. Drug

    Aprocitentan

    go.drugbank.com/drugs/DB15059
    ApprovedInvestigational

    blocker, and a diuretic at maximally tolerated doses. … Aprocitentan is a dual antagonist of endothelin receptors A and B used for treatment-resistant hypertension. It is the active metabolite of [macitentan].

  8. Drug

    Givosiran

    go.drugbank.com/drugs/DB15066
    Approved

    Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. … [L10202] It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder

  9. Drug

    Cusatuzumab

    go.drugbank.com/drugs/DB15100
    Investigational

    [A241975] Cusatuzumab is a humanized IgG1 antibody targeted against CD70. … An overexpression of CD70 can result in the proliferation of malignant cells and has been documented in a variety of solid and hematological malignancies.

  10. Drug

    Pemigatinib

    go.drugbank.com/drugs/DB15102
    ApprovedInvestigational

    Pemigatinib is a small molecule kinase inhibitor with antitumour activity. … [A193719] FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide variety of cancers including those of the urinary bladder, breast